Oct. 5 (Bloomberg) -- Gedeon Richter Nyrt., Hungary’s biggest drugmaker, and Forest Laboratories Inc. reported today “positive” results from a Phase III clinical trial of cariprazine, an antipsychotic agent.
Data showed that patients with acute manic episodes who were treated with cariprazine “experienced significant symptom improvement compared with placebo-treated patients,” the two companies said in a statement posted on the website of the Budapest Stock Exchange today.
--Editor: Alan Purkiss
To contact the reporter on this story: Andras Gergely in Budapest at email@example.com
To contact the editor responsible for this story: Gavin Serkin at firstname.lastname@example.org